Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial

Jack R. Cornelius, Tammy Chung, Antoine B. Douaihy, Levent Kirisci, Jody Glance, Julie Kmiec, Douglas FitzGerald, Maribeth A. Wesesky, Ihsan M Salloum

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This was a first double-blind, placebo-controlled pilot study to evaluate the efficacy of the novel antidepressant medication mirtazapine for treating both the depressive symptoms and the level of alcohol consumption of subjects with comorbid major depressive disorder and an alcohol use disorder (MDD/AUD). The results of two previous studies of mirtazapine in MDD/AUD subjects had suggested efficacy for mirtazapine for decreasing their level of depressive symptoms, but level of alcohol consumption had not been assessed in those studies. All subjects in this 12-week pilot study were randomized to either mirtazapine or placebo, and also received motivational enhancement therapy. Between-group analyses involving the outcome measures of depressive symptoms, level of alcohol consumption, and level of alcohol craving indicated no significant differences between groups, possibly because of limited sample size. However, within-group t tests in the mirtazapine group showed a significant decrease in depressive symptoms by week 2, also noted at all subsequent assessments (weeks 3, 4, 6, 8, 10, and 12) during the 12-week study. In contrast, no significant decrease in depressive symptoms was noted in the placebo group until week 8. No evidence of efficacy was found for mirtazapine for decreasing level of alcohol consumption in MDD /AUD subjects.

Original languageEnglish (US)
Pages (from-to)326-330
Number of pages5
JournalPsychiatry Research
Volume242
DOIs
StatePublished - Aug 30 2016

Fingerprint

Placebos
Alcohols
Depression
Alcohol Drinking
Major Depressive Disorder
Sample Size
Antidepressive Agents
mirtazapine
Outcome Assessment (Health Care)
Therapeutics

Keywords

  • Alcohol use disorder
  • Comorbid
  • Major depression
  • Mirtazapine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Mirtazapine in comorbid major depression and an alcohol use disorder : A double-blind placebo-controlled pilot trial. / Cornelius, Jack R.; Chung, Tammy; Douaihy, Antoine B.; Kirisci, Levent; Glance, Jody; Kmiec, Julie; FitzGerald, Douglas; Wesesky, Maribeth A.; Salloum, Ihsan M.

In: Psychiatry Research, Vol. 242, 30.08.2016, p. 326-330.

Research output: Contribution to journalArticle

Cornelius, JR, Chung, T, Douaihy, AB, Kirisci, L, Glance, J, Kmiec, J, FitzGerald, D, Wesesky, MA & Salloum, IM 2016, 'Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial', Psychiatry Research, vol. 242, pp. 326-330. https://doi.org/10.1016/j.psychres.2016.06.005
Cornelius, Jack R. ; Chung, Tammy ; Douaihy, Antoine B. ; Kirisci, Levent ; Glance, Jody ; Kmiec, Julie ; FitzGerald, Douglas ; Wesesky, Maribeth A. ; Salloum, Ihsan M. / Mirtazapine in comorbid major depression and an alcohol use disorder : A double-blind placebo-controlled pilot trial. In: Psychiatry Research. 2016 ; Vol. 242. pp. 326-330.
@article{30543125899c424fbb0e99ca04705b5b,
title = "Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial",
abstract = "This was a first double-blind, placebo-controlled pilot study to evaluate the efficacy of the novel antidepressant medication mirtazapine for treating both the depressive symptoms and the level of alcohol consumption of subjects with comorbid major depressive disorder and an alcohol use disorder (MDD/AUD). The results of two previous studies of mirtazapine in MDD/AUD subjects had suggested efficacy for mirtazapine for decreasing their level of depressive symptoms, but level of alcohol consumption had not been assessed in those studies. All subjects in this 12-week pilot study were randomized to either mirtazapine or placebo, and also received motivational enhancement therapy. Between-group analyses involving the outcome measures of depressive symptoms, level of alcohol consumption, and level of alcohol craving indicated no significant differences between groups, possibly because of limited sample size. However, within-group t tests in the mirtazapine group showed a significant decrease in depressive symptoms by week 2, also noted at all subsequent assessments (weeks 3, 4, 6, 8, 10, and 12) during the 12-week study. In contrast, no significant decrease in depressive symptoms was noted in the placebo group until week 8. No evidence of efficacy was found for mirtazapine for decreasing level of alcohol consumption in MDD /AUD subjects.",
keywords = "Alcohol use disorder, Comorbid, Major depression, Mirtazapine",
author = "Cornelius, {Jack R.} and Tammy Chung and Douaihy, {Antoine B.} and Levent Kirisci and Jody Glance and Julie Kmiec and Douglas FitzGerald and Wesesky, {Maribeth A.} and Salloum, {Ihsan M}",
year = "2016",
month = "8",
day = "30",
doi = "10.1016/j.psychres.2016.06.005",
language = "English (US)",
volume = "242",
pages = "326--330",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Mirtazapine in comorbid major depression and an alcohol use disorder

T2 - A double-blind placebo-controlled pilot trial

AU - Cornelius, Jack R.

AU - Chung, Tammy

AU - Douaihy, Antoine B.

AU - Kirisci, Levent

AU - Glance, Jody

AU - Kmiec, Julie

AU - FitzGerald, Douglas

AU - Wesesky, Maribeth A.

AU - Salloum, Ihsan M

PY - 2016/8/30

Y1 - 2016/8/30

N2 - This was a first double-blind, placebo-controlled pilot study to evaluate the efficacy of the novel antidepressant medication mirtazapine for treating both the depressive symptoms and the level of alcohol consumption of subjects with comorbid major depressive disorder and an alcohol use disorder (MDD/AUD). The results of two previous studies of mirtazapine in MDD/AUD subjects had suggested efficacy for mirtazapine for decreasing their level of depressive symptoms, but level of alcohol consumption had not been assessed in those studies. All subjects in this 12-week pilot study were randomized to either mirtazapine or placebo, and also received motivational enhancement therapy. Between-group analyses involving the outcome measures of depressive symptoms, level of alcohol consumption, and level of alcohol craving indicated no significant differences between groups, possibly because of limited sample size. However, within-group t tests in the mirtazapine group showed a significant decrease in depressive symptoms by week 2, also noted at all subsequent assessments (weeks 3, 4, 6, 8, 10, and 12) during the 12-week study. In contrast, no significant decrease in depressive symptoms was noted in the placebo group until week 8. No evidence of efficacy was found for mirtazapine for decreasing level of alcohol consumption in MDD /AUD subjects.

AB - This was a first double-blind, placebo-controlled pilot study to evaluate the efficacy of the novel antidepressant medication mirtazapine for treating both the depressive symptoms and the level of alcohol consumption of subjects with comorbid major depressive disorder and an alcohol use disorder (MDD/AUD). The results of two previous studies of mirtazapine in MDD/AUD subjects had suggested efficacy for mirtazapine for decreasing their level of depressive symptoms, but level of alcohol consumption had not been assessed in those studies. All subjects in this 12-week pilot study were randomized to either mirtazapine or placebo, and also received motivational enhancement therapy. Between-group analyses involving the outcome measures of depressive symptoms, level of alcohol consumption, and level of alcohol craving indicated no significant differences between groups, possibly because of limited sample size. However, within-group t tests in the mirtazapine group showed a significant decrease in depressive symptoms by week 2, also noted at all subsequent assessments (weeks 3, 4, 6, 8, 10, and 12) during the 12-week study. In contrast, no significant decrease in depressive symptoms was noted in the placebo group until week 8. No evidence of efficacy was found for mirtazapine for decreasing level of alcohol consumption in MDD /AUD subjects.

KW - Alcohol use disorder

KW - Comorbid

KW - Major depression

KW - Mirtazapine

UR - http://www.scopus.com/inward/record.url?scp=84974855143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974855143&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2016.06.005

DO - 10.1016/j.psychres.2016.06.005

M3 - Article

C2 - 27327217

AN - SCOPUS:84974855143

VL - 242

SP - 326

EP - 330

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

ER -